Articles related to LEUKEMIA

Five-year survival rates for chronic lymphocytic leukemia show promising outcomes even in elderly patients, with 77% survival in those 75 and older.

The study’s findings highlight the complex interplay between CAR T cell therapy and cytokine signaling in AML treatment, suggesting new avenues for improving outcomes in this challenging disease.

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

Lisocabtagene maraleucel offers a new treatment option for patients with CLL who have progressed on both BTK and BCL2 inhibitors, addressing an important unmet need in this patient population.

The addition of blinatumomab to consolidation chemotherapy in adults with MRD-negative B-cell precursor ALL demonstrated a significant improvement in overall survival. At 3 years, the overall survival rate was 85% in the blinatumomab group compared to 68% in the chemotherapy-only group.